Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection
Rattachement africain : it, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Identifying stage-specific antigens is essential for developing tuberculosis (TB) diagnostics and vaccines. In a low TB endemic country, we characterized, the Mycobacterium tuberculosis (Mtb)-specific immune response to a pool of Mtb-derived epitopes (ATB116), demonstrated as associated with TB disease. Methods In this prospective observational cross-sectional study, we enrolled healthy donors (HD), subjects with TB disease, and TB infection (TBI) at baseline and therapy completion. T-cell response after whole blood stimulation with the peptide pools was characterized by ELISA, flow cytometry, and multiplex assay. Results ATB116-specific IFN-γ response (by ELISA) significantly associates with Mtb regardless of infection/disease (p < 0.0001) and decreases during TB therapy (p = 0.0002). Flow cytometry confirms that ATB116-specific CD4 + T-cell response associated with Mtb regardless of infection/disease (p < 0.0001) and shows a significantly higher frequency of IFN-γ/IL-2 and central memory T-cells in TBI compared to TB (p = 0.016; p = 0.0242, respectively). CD4 + T cell-specific response decreases after TB therapy completion. The antigen-specific CD8 + T-cell response mirrors the CD4 + response. Finally, the multiplex assay analysis showed that ATB116 induces several immune factors in both TB and TBI. Conclusion We characterized the immune response to Mtb peptide pools that is modulated by TB therapy. These results are important for our understanding of TB immunopathogenesis and vaccine design.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Therapy modulates the response to T cell epitopes over the spectrum of tuberculosis infection
- Date Crossref
- 01/12/2024
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani pays non établi dans la noticeÉtablissement de santé
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
La Jolla Institute for Immunology Center for Vaccine Innovation pays non établi dans la noticeOrganisation à but non lucratif
-
Translational Research Unit pays non établi dans la noticeStructure de recherche
-
National Institute for Infectious Diseases "Lazzaro Spallanzani"-IRCCS Respiratory Unit pays non établi dans la noticeStructure de recherche
-
University of California San Diego (UCSD) La Jolla Institute for Immunology (LJI) pays non établi dans la noticeUniversité ou école supérieure
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Istituti di Ricovero e Cura a Carattere Scientifico et Center for Vaccine Innovation — La Jolla Institute for Immunology, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.